Unilever
UL
60.98
+0.18
+0.30%
Unilever
US · UL
#153 by market cap
Listed 1970
60.98
+0.18
+0.30%
Live - 5344 symbols - heartbeat 121s ago
· 2026-10-08 07:27
Pre-market
61.06
+0.13%
After-hours
60.98
0.00%
Overnight
60.69
-0.48%
- Market cap
- 131.32B
- P/E (TTM)i
- 12.85
- P/Bi
- 7.24
- EPSi
- 4.84
- Div yieldi
- 3.65%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on UL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.48, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -3.77% YoY
Margins
- Gross margin
- 46.95%
- Operating margin
- 20.05%
- Net margin
- 18.75%
Key ratios & quality
- Enterprise valuei
- 152.86B
- PEG ratioi
- 1.73
- Altman Z-Scorei
- 3.48
PEG uses trailing P/E against the 3-year net income growth rate (7.41%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.98B | 51.98B | 50.72B | 52.44B | 60.07B | 51.68B | 52.48B | 50.50B |
| Gross profit | 22.28B | 22.88B | 22.04B | 22.19B | 24.17B | 22.50B | 24.50B | 23.71B |
| Selling & admin expenses | 11.92B | 12.09B | 11.87B | 11.70B | 13.58B | 13.35B | 14.31B | 13.71B |
| Research & development | 900.00M | 840.00M | 800.00M | 847.00M | 908.00M | 949.00M | 987.00M | -- |
| Operating profit | 9.44B | 9.92B | 9.37B | 9.64B | 9.73B | 9.28B | 10.28B | 10.13B |
| Pretax profit | 12.36B | 8.29B | 8.00B | 8.56B | 10.34B | 8.63B | 8.37B | 8.69B |
| Tax | 2.57B | 2.26B | 1.92B | 1.94B | 2.07B | 1.99B | 2.33B | 2.48B |
| Net profit | 9.79B | 6.03B | 6.07B | 6.62B | 8.27B | 7.14B | 6.37B | 10.01B |
| Basic EPS | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| Diluted EPS | 3.92 | 2.41 | 2.39 | 2.61 | 3.36 | 2.89 | 2.58 | 4.32 |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 15.48B | 16.43B | 16.16B | 17.40B | 19.16B | 17.90B | 19.19B | 17.07B |
| Cash & ST investments | 3.91B | 5.07B | 6.30B | 4.85B | 5.84B | 6.11B | 7.63B | 5.01B |
| Inventory | 4.30B | 4.16B | 4.46B | 4.68B | 5.93B | 5.12B | 5.18B | 4.04B |
| Total assets | 61.11B | 64.81B | 67.66B | 75.10B | 77.82B | 75.27B | 79.75B | 70.47B |
| Total current liabilities | 20.15B | 20.98B | 20.59B | 24.78B | 25.43B | 23.51B | 25.23B | 21.66B |
| Short-term debt | 3.34B | 4.45B | 4.29B | 7.06B | 5.57B | 4.90B | 6.20B | 2.46B |
| Long-term debt | 21.26B | 21.82B | 21.09B | 21.33B | 21.80B | 22.63B | 23.29B | 24.09B |
| Total liabilities | 48,994,000,000.00 | 50,920,000,000.00 | 50,004,000,000.00 | 55,349,000,000.00 | 56,120,000,000.00 | 54,502,000,000.00 | 57,195,000,000.00 | 52,884,000,000.00 |
| Total equity | 12.12B | 13.89B | 17.66B | 19.75B | 21.70B | 20.76B | 22.56B | 17.59B |
| Retained earnings | 26.02B | 18.21B | 22.55B | 46.75B | 50.25B | 47.05B | 49.72B | 44.23B |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 17.90B | 20.22B | 19.19B | 19.19B | 17.07B | 21.39B |
| Cash & ST investments | 6.11B | 6.34B | 7.63B | 5.31B | 5.01B | 5.87B |
| Inventory | 5.12B | 5.62B | 5.18B | 5.50B | 4.04B | 4.52B |
| Total assets | 75.27B | 79.83B | 79.75B | 76.00B | 70.47B | 76.93B |
| Total current liabilities | 23.51B | 26.13B | 25.23B | 25.10B | 21.66B | 28.89B |
| Short-term debt | 4.90B | -- | 6.20B | -- | 2.46B | -- |
| Long-term debt | 22.63B | -- | 23.29B | -- | 24.09B | -- |
| Total liabilities | 54,502,000,000.00 | 56,809,000,000.00 | 57,195,000,000.00 | 56,068,000,000.00 | 52,884,000,000.00 | 58,626,000,000.00 |
| Total equity | 20.76B | 23.02B | 22.56B | 19.93B | 17.59B | 18.31B |
| Retained earnings | 47.05B | 49.57B | 49.72B | 50.70B | 44.23B | 45.93B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.32B | 8.11B | 9.06B | 7.97B | 7.28B | 9.43B | 9.52B | 8.35B |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | 5.79B | 6.58B | 8.04B | 6.63B | 5.57B | 7.99B | 7.91B | 6.76B |
| Dividends paid | -4.07B | -4.21B | -4.28B | -4.48B | -4.33B | -4.36B | -4.32B | -4.45B |
| Stock buybacks / issuance | -6.28B | -201.00M | 0 | -3.02B | -1.51B | -1.51B | -1.51B | -1.51B |
| Ending cash balance | 3.09B | 4.12B | 5.48B | 3.39B | 4.23B | 4.05B | 5.95B | 3.87B |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 74.51 | 45.43 | 39.22 | 37.37 | 42.31 | 34.95 | 30.16 | 53.32 |
| ROA %i | 15.68 | 9.05 | 8.43 | 8.47 | 10.00 | 8.47 | 7.41 | 12.61 |
| ROIC %i | 26.61 | 15.64 | 14.29 | 14.23 | 17.00 | 14.80 | 12.79 | 21.26 |
| 5-year avg ROE %i | 43.67 | 45.43 | 46.53 | 47.48 | 47.91 | 39.92 | 36.80 | 39.62 |
| EBIT margin %i | 25.47 | 17.41 | 17.15 | 17.28 | 18.52 | 17.47 | 16.44 | 19.39 |
| FCF / sales %i | 10.24 | 12.66 | 15.84 | 12.65 | 9.28 | 12.89 | 12.42 | 13.38 |
| Current ratioi | 0.77 | 0.78 | 0.78 | 0.70 | 0.75 | 0.76 | 0.76 | 0.79 |
| Quick ratioi | 0.52 | 0.56 | 0.55 | 0.40 | 0.49 | 0.47 | 0.51 | 0.57 |
| Debt / assetsi | 42.85 | 42.90 | 39.56 | 39.51 | 36.54 | 37.99 | 38.44 | 177.70 |
| LT debt / equityi | 200.48 | 177.03 | 147.26 | 132.17 | 120.23 | 130.88 | 122.33 | 161.88 |
| Interest coveragei | 21.50 | 11.86 | 12.37 | 17.84 | 14.10 | 9.69 | 8.93 | 8.92 |
| Revenue CAGR (3Y) %i | -1.45 | -0.47 | -1.89 | 0.95 | 4.94 | 0.62 | 0.02 | -5.62 |
| Net income CAGR (3Y) %i | 24.04 | 2.76 | -2.51 | -13.57 | 10.75 | 5.14 | -1.71 | 7.41 |
| FCF CAGR (3Y) %i | 4.10 | 9.52 | 8.97 | 4.65 | -5.40 | -0.19 | 6.03 | 6.64 |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 34.95 | 33.57 | 30.16 | 29.16 | 53.32 | 54.56 |
| ROA %i | 8.47 | 8.39 | 7.41 | 7.13 | 12.61 | 12.13 |
| ROIC %i | 14.80 | 36.30 | 12.79 | 31.72 | 21.26 | 57.57 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 17.47 | 17.92 | 16.44 | 15.83 | 19.39 | 19.62 |
| FCF / sales %i | 12.89 | 12.50 | 12.42 | 10.77 | 13.38 | 13.86 |
| Current ratioi | 0.76 | 0.77 | 0.76 | 0.76 | 0.79 | 0.74 |
| Quick ratioi | 0.47 | 0.55 | 0.51 | 0.52 | 0.57 | 0.56 |
| Debt / assetsi | 37.99 | -- | 38.44 | -- | 177.70 | -- |
| LT debt / equityi | 130.88 | -- | 122.33 | -- | 161.88 | -- |
| Interest coveragei | 9.69 | 9.25 | 8.93 | 8.89 | 8.92 | 8.61 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Personal Care is the largest reported line at 26.06% of revenue, across 4 reported segments.
- No single line clears half of revenue; Foods is next at 25.60%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Personal Care26.06%
Foods25.60%
Beauty & Wellbeing25.44%
Home Care22.90%
Region
Others62.50%
United States20.78%
India12.31%
United Kingdom4.41%
Quote time 2026-10-08 07:27:50 · For reference only, not investment advice and not tailored to your situation.